Natalizumab, a humanized monoclonal antibody directed against α4-integrin is a first-in-class disease-modifying therapy for the treatment of relapsing multiple sclerosis. Natalizumab is highly effective but has been associated with a risk of progressive multifocal leukoencephalopathy. Since the efficacy of natalizumab in relapsing forms of multiple sclerosis is viewed as superior to first-line agents, a growing number of neurologists are using natalizumab as the treatment of choice for patients with worsening MS. Owing to the recently reported cases of progressive multifocal leukoencephalopathy, a panel of neurologists met in February 2009 to discuss best practices for the use of natalizumab, with the goal of developing consensus-based recommendations on patient management to minimize the risk of progressive multifocal leukoencephalopathy. The panel consisted of a cross section of academic and community neurologists from the United States who treat multiple sclerosis in large centers and have extensive experience with natalizumab (approximating 2000 patient-years combined experience). This paper summarizes the panel's recommendations on the following: (1) appropriate patient selection for natalizumab; (2) routine monitoring and management of adverse events during natalizumab therapy; and (3) clinical vigilance monitoring and risk reduction for progressive multifocal leukoencephalopathy.
SheremataWA, VollmerTL, StoneLA, Willmer-HulmeA J, KollerM.A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology1999; 52: 1072–1074.
2.
KentSJ, KarlikSJ, CannonC.A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol1995; 58: 1–10.
3.
YednockTA, CannonC, FritzLC, Sanchez-MadridF, SteinmanL, KarinN.Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–66.
FergusonTA, MizutaniH, KupperTS.Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc Natl Acad Sci USA1991; 88: 8072–8076.
6.
ChanPY, AruffoA.VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem1993; 268: 24655–24664.
7.
PolmanCH, O'ConnorPW, HavrdovaE.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
8.
GiovannoniG, KinkelRP, VartanianT.Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Rev Neurol Dis2007; 4: 184–193.
9.
European Medicines Agency.EPARs for authorised medicinal products for human use: Tysabri, 20 February 2009.
10.
FDA. Our STN: BL 125104/15 (Tysabri approval), 5 June 2006. Department of Health and Human Services.
11.
PolmanCH, GoodmanAD, KapposL.Safety and effectiveness of natalizumab re-dosing and treatment in the STRATA study. World Congress on Treatment and Research in Multiple Sclerosis, 2008.
12.
HydeR, BozicC, BelcherG, Dong-SiT, KimR, LynnF, Kooijans-CoutinhoM, PanzaraMA.Utilization and safety of natalizumab in patients with relapsing multiple sclerosis in the post-marketing setting. World Congress of Neurology, FP33-WE-04, 28 October 2009.
13.
Biogen Idee Inc., Elan Pharmaceuticals I.TYSABRI Prescribing Information, US Food and Drug Administration, 1 August 2008.
14.
EdwardsS, ZvartauM, ClarkeH, IrvingW, BlumhardtLD.Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry1998; 64: 736–741.
15.
BarkhofF, ScheltensP, FrequinST.Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol1992; 159: 1041–1047.
16.
RudickRA, StuartWH, CalabresiPA.Natalizumab plus interferon beta-la for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
17.
JefferyD, FrankJ, CaiB.The European Interferon Beta 1-b Secondary Progressive Multiple Sclerosis Investigatiors. Change in T2 MRI lesion burden predicts progression of clinical disability in seconday progressive multple sclerosis. Mult Scler2001; 7: S44.
18.
CoylePK.Switching algorithms: from one immunomodulatory agent to another. J Neurol2008; 255(Suppl 1): 44–50.
19.
LimmrothV, MalessaR, ZettlUK.Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol2007; 254: 67–77.
20.
ZwibelHL.Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurol Scand2006; 113: 378–386.
21.
CaonC, DinM, ChingW, TselisA, LisakR, KhanO.Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol2006; 13: 471–474.
22.
CarraA, OnahaP, LueticG.Drop outs analysis: 10 years follow-up in a cohort of relapsing-remitting multiple sclerosis patients in Argentina treated with interferons or glatiramer acetate. Mult Scler2006; 12(Suppl 1): S84.
23.
GajofattoA, BacchettiP, GrimesB, HighA, WaubantE.Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler2009; 15: 50–58.
24.
VallittuAM, PeltoniemiJ, ElovaaraI.The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Acta Neurol Scand2005; 112: 234–237.
25.
European Medicines Agency.Tysabri Product Information, 2009.
26.
NaismithRT, TrinkausK, CrossAH.Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler2006; 12: 775–781.
27.
GoldR, JawadA, MillerDH.Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J Neuroimmunol2007; 187: 156–158.
28.
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. Cytotherapy2001; 3: 41–54.
29.
MasurH, KaplanJE, HolmesKK.Guidelines for preventing opportunistic infections among HIV-infected per-sons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med2002; 137: 435–478.
30.
TrikalinosTA, IoannidisJP.Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis2001; 33: 1901–1909.
31.
AbgrallS, RabaudC, CostagliolaD.Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis2001; 33: 1747–1755.
32.
KapposL, BatesD, HartungHP.Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol2007; 6: 431–441.
33.
Food and Drug Administration.Natalizumab Liver injury: 2 case reports. Reactions2008; 1207: 26.
34.
Biogen Idee Inc., Elan Pharmaceuticals I.Dear Healthcare Provider: Important Safety Information, 2008.
35.
Biogen Idee Inc. (2006). AVONEX Prescribing Information. US Food and Drug Administration.
36.
SeronoI.REBIF Prescribing Information, US Food and Drug Administration, 2005.
37.
Berlex Laboratories. (2003). BETASERON Prescribing Information. US Food and Drug Administration.
38.
TremlettH, SeemullerS, ZhaoY, YoshidaEM, OgerJD, PetkauJ.Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology2006; 67: 1291–1293.
39.
KaszubowskaL.Telomere shortening and ageing of the immune system. J Physiol Pharmacol2008; 59(Suppl 9): 169–186.
40.
JohnsonRW, WasnerG, SaddierP, BaronR.Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging2008; 25: 991–1006.
41.
MarkowitzJS, PashkoS, GuttermanEM, Linde-ZwirbleWT, NewboldRIII. Death rates among patients hospitalized with community-acquired pneumonia: a reexamination with data from three states. Am J Public Health1996; 86: 1152–1154.
42.
FranceschiC, BonafeM, ValensinS.Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine2000; 18: 1717–1720.
43.
HartungHP, GonsetteR, KonigN.Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet2002; 360: 2018–2025.
44.
LenzHJ.Management and preparedness for infusion and hypersensitivity reactions. Oncologist2007; 12: 601–609.
45.
The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol2005; 115: S483–S523.
46.
PhillipsJT, FrohmanEM.Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis. Therap Adv Neurol Disord2008; 1: 151–153.
47.
KrumbholzM, PellkoferH, GoldR, HoffmannLA, HohlfeldR, KumpfelT.Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol2007; 64: 1331–1333.
48.
HellwigK, SchimrigkS, FischerM.Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol2008; 65: 656–658.
49.
KillesteinJ, JasperseB, LiedorpM, SeewannA, PolmanC.Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies. Mult Scler2009; 15: 525–526.
50.
CheifetzA, SmedleyM, MartinS.The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol2003; 98: 1315–1324.
51.
CalabresiPA.Diagnosis and management of multiple sclerosis. Am Fam Physician2004; 70: 1935–1944.
52.
FoleyJ.Natalizumab discontinuation predisposes to serious infusion related reactions and antibody formation. Mult Scler2007; 13: 1223.
53.
O'ConnorP, GoodmanAD, KapposL.Safety of natalizumab upon re-dosing: preliminary results from the STRATA study. Mult Scler2007; 13(Suppl 2): S168–S169.
54.
CernikC, GallinaK, BrodellRT.The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med2008; 168: 1137–1144.
FDA. (2009). Tysabrf® Risk Minimization Action Plan: Summary of TOUCH(tm).Food and Drug Administration.
57.
MitchellAJ, Benito-LeonJ, GonzalezJM, Rivera-NavarroJ.Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol2005; 4: 556–566.
58.
HoogervorstEL, EikelenboomM J, UitdehaagBM, PolmanCH.One year changes in disability in multiple sclerosis: neurological examination compared with patient self report. J Neurol Neurosurg Psychiatry2003; 74: 439–442.
59.
BenedictRH, CoxD, ThompsonLL, FoleyF, Weinstock-GuttmanB, MunschauerF.Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler2004; 10: 675–678.
60.
WilkenJA, KaneR, SullivanCL.The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult Scler2003; 9: 119–127.
61.
ParmenterBA, Weinstock-GuttmanB, GargN, MunschauerF, BenedictRH.Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test. Mult Scler2007; 13: 52–57.
62.
KhatriBO, ManS, GiovannoniG.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology2009; 72: 402–409.
63.
CrowderCD, GyureKA, DrachenbergCB.Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant2005; 5: 1151–1158.
64.
U.S. National Institutes of Health. (2009). Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML).NIH.
65.
HartungH-P.New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. The Lancet2009; 8: 28–31.
66.
O'ConnorP, GoodmanAD, KapposL.Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Mult Scler2006; 12: S17.
67.
YousryTA, MajorEO, RyschkewitschC.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. iV Engl J Med2006; 354: 924–933.
68.
BozicC, BelcherG, KimR, HydeR, Kooijmans-CoutinhoM, PanzaraM.Natalizumab in Patients with Relapsing Multiple Sclerosis: Updated Utilization and Safety Results Including TOUCH and TYGRIS, American Academy of Neurology, S11.005, 28 April 2009.
69.
MillerDH, KhanOA, SheremataWA.A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
70.
RoseJ, FoleyJ, CarlsonN.Monoclonal antibody treatments for multiple sclerosis current treatment options. Neurology2009; 11: 211–220.
